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OBJECTIVES We sought to determine, in a double-blind, placebo-controlled, randomized study, whether
vitamin E supplementation (1,000 IU for three months) would improve impaired conduit and
resistance vessel endothelial vasodilator function (EVF) and systemic arterial compliance
(SAC) in type I diabetes mellitus (DM).
BACKGROUND Oxidative stress is thought to be important in the pathogenesis of impaired EVF. Consistent
with this hypothesis, we have recently shown that impaired EVF is related to low density
lipoprotein (LDL) vitamin E content (VEC) in young subjects with type 1 DM.
METHODS We assessed EVF in the brachial artery (using noninvasive ultrasound, flow-mediated
vasodilation [FMD]; n 5 41) and in the forearm resistance vessels (by flow responses to
intrabrachial acetylcholine [ACh]; n 5 21) and measured SAC (simultaneous aortic blood
flow and carotid pressure measurements; n 5 41) before and after active or placebo therapy.
RESULTS The LDL VEC was increased by 127% after supplementation, resulting in a significant
reduction in the oxidative susceptibility of LDL. There was no time-dependent change in
FMD or in the response to ACh or SAC in the placebo group. A significant improvement
in FMD (2.6 6 0.6% to 7.0 6 0.7%, p , 0.005) and the dose response to ACh (p , 0.05)
were observed in those randomized to vitamin E therapy. Systemic arterial compliance was
not affected by vitamin E (0.41 6 0.03 vs. 0.49 6 0.06 arbitrary compliance units, p 5 NS).
The change in FMD was related to the change in LDL VEC (r 5 0.42, p , 0.05) and the
change in the oxidative susceptibility of LDL (r 5 0.64, p , 0.0001).
CONCLUSIONS Short-term daily oral supplementation with vitamin E improves EVF in both the conduit and
resistance vessels of young subjects with type I DM. (J Am Coll Cardiol 2000;36:94–102) ©
2000 by the American College of Cardiology
Impaired endothelial vasodilator function (EVF) of the
conduit (1) and resistance (2–4) vessels, together with
impaired arterial compliance (5,6), is a feature of type I
diabetes mellitus (DM), even in the absence of clinically
detectable complications. These and other abnormalities of
the arterial circulation are promoted in part by lipid abnor-
malities (7), hyperglycemia (8) and hyperinsulinemia (9). In
turn, these factors may produce their pathogenic effects by
glycooxidation of proteins and lipids (10) and activation of
the polyol pathway (11), with increased free radical produc-
tion (10), as well as activation of protein kinase C (PKC)
(12).
The observation that vitamin E can decrease the suscep-
tibility of low density lipoprotein (LDL) to oxidation (13),
quench free radicals and reduce activation of PKC (14),
among a number of other actions, has raised the possibility
of an antiatherogenic role for this lipid-soluble antioxidant.
Indeed, consistent with this, epidemiologic studies have
demonstrated an inverse relation between vitamin E and
cardiovascular disease (15,16), as well as the severity of
coronary artery disease (17).
We have previously shown that plasma and LDL vitamin
E is reduced in young diabetic patients with impaired EVF
and that there is a direct relation between LDL vitamin E
and endothelial function in this group (18). Several (19–
22), but not all (23), experimental studies have found that
vitamin E supplementation can improve endothelial func-
tion in hypercholesterolemic and diabetic models. This
effect of vitamin E has not been replicated in most clinical
studies (24–26), including type II DM (27), although
improvement in arterial compliance (28) and carotid intima–
media thickness (29) has been noted. The effect of vitamin
E supplementation on endothelial function in type I DM
has not been assessed. However, we have previously shown
that LDL vitamin E content (VEC) is reduced in type I
DM (18) and that EVF in the forearm is related to LDL
VEC (18). This has also recently been demonstrated in the
coronary circulation (30). In view of our findings, we
undertook a randomized, placebo-controlled trial in young
patients with type I DM to examine the effect of three
months of therapy with oral vitamin E (1,000 IU) on
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conduit and resistance vessel EVF and systemic arterial
compliance (SAC), as this may in part be endothelium-
dependent.
METHODS
Subjects. Forty-one subjects with type I DM were re-
cruited by advertisement and participated in this study,
which was approved by the Human Research Ethics Com-
mittee of Monash Medical Centre. All subjects gave writ-
ten, informed consent. None of the subjects were taking any
vasoactive medications. All of the diabetics were treated
with insulin. The average daily total insulin dose was 70 6
27 U (mean 6 SD). The duration of disease was on average
110 6 75 months (mean 6 SD). None of the diabetics had
clinical evidence of hypertension, retinopathy or neuropa-
thy, and albumin excretion rates were normal (,20 mg/min)
in all of them.
Experimental design. The 41 diabetic subjects were ran-
domized in a double-blind manner to receive three months
of treatment with 1,000 IU/day of oral vitamin E (all-rac-
alpha-tocopherol) (Hellay Laboratories, Victoria, Australia)
or placebo (Hellay Laboratories, Victoria, Australia).
Twenty-one subjects were randomized to receive placebo
and 20 to active therapy. All diabetic subjects had flow-
mediated vasodilation (FMD), brachial artery responses to
nitroglycerin (NTG) and SAC measured before and after
therapy. In addition, a subset of 20 diabetics (10 on placebo
and 10 on active therapy) underwent studies of the resis-
tance vessels using venous occlusion plethysmography be-
fore and after three months of therapy. The subjects were
reviewed at six weeks to check glycemic control and to
monitor for any adverse events.
General procedure. Subjects attended the laboratory in
fasted condition, having refrained from aspirin and nonste-
roidal anti-inflammatory drugs for at least five days before
the study and caffeine-containing beverages for 12 h, as
described previously (2). Blood glucose levels were docu-
mented at the time of brachial artery ultrasound and twice
during venous occlusion plethysmography (Table 1).
Brachial artery ultrasound. Endothelium-dependent and
-independent vasodilation was assessed in the brachial artery
using transcutaneous ultrasound, as described by our group
previously (31), using a high resolution ultrasound machine
(ATL, HDI Ultramark 9, Seattle, Washington) with a 7- to
10-MHz linear-array transducer. Endothelium-dependent
FMD was assessed as the percent change in arterial diam-
eter in response to reactive hyperemia associated with 5 min
of ischemia. Endothelium-independent vasodilation was
assessed in response to a single tablet of sublingual NTG.
Venous occlusion plethysmography. Forearm blood flow
(milliliters per 100 ml forearm tissue per min) measurement
was achieved by this well-validated technique (32), as
described by this group previously (2,33). A 20-gauge, 5-cm
polyethylene catheter (Cook, Brisbane, Australia) was in-
troduced into the brachial artery of the nondominant
forearm under local anesthesia under aseptic conditions.
The arterial line was used for on-line measurement of blood
pressure and for direct intra-arterial drug infusions.
DRUG INFUSION PROTOCOL. All drugs were infused for
3 min at a rate of 0.4 ml/min before commencing measure-
ment of forearm blood flow. Forearm blood flow responses
were then measured continuously for 2 min while continu-
ing infusion of each dose of drug. Endothelium-dependent
vasodilation was assessed in response to acetylcholine (ACh)
chloride (Miochol, Iolab Pharmaceuticals, Sydney, Austra-
lia) at doses of 2.7, 9 and 27 mg/min cumulatively.
Endothelium-independent vasodilation was assessed in re-
Abbreviations and Acronyms
ACh 5 acetylcholine
ANOVA 5 analysis of variance
DM 5 diabetes mellitus
EVF 5 endothelial vasodilator function
FMD 5 flow-mediated vasodilation
LDL 5 low density lipoprotein
NTG 5 nitroglycerin
PKC 5 protein kinase C
SAC 5 systemic arterial compliance
VEC 5 vitamin E content
Table 1. Baseline Morphometric Characteristics and Glycemic Control of the Diabetic
Subgroups Randomized to Placebo or Vitamin E Therapy
Characteristics
Placebo Group
(n 5 21)
Vitamin E Group
(n 5 20)
Age (yrs) 28 6 5 23 6 6
Gender (M/F) 10/11 9/11
Body mass index (kg/m2) 25.5 6 0.7 24.3 6 0.6
Duration of diabetes (months) 119 6 60 110 6 71
HbA1C (%) 8.8 6 0.4 9.5 6 0.5
Fasting glucose (mmol/liter) 11.8 6 3.2 12.7 6 1.2
Ambient glucose FMD (mmol/liter) 12.0 6 1.1 11.2 6 1.2
First ambient glucose VOP (mmol/liter) 11.2 6 1.1 10.4 6 1.7
Second ambient glucose VOP (mmol/liter) 10.9 6 0.3 10.7 6 1.7
Data are presented as the mean value 6 SD.
F 5 females; FMD 5 flow-mediated dilation; HbA1C 5 glycosylated hemoglobin; M 5 males; VOP 5 venous occlusion
plethysmography.
95JACC Vol. 36, No. 1, 2000 Skyrme-Jones et al.
July 2000:94–102 Vitamin E Therapy in Type I Diabetes Mellitus
sponse to sodium nitroprusside (Faulding, Melbourne, Aus-
tralia) at a dose of 9 mg/min.
Systemic arterial compliance. The assessment of SAC
was carried out noninvasively using the area method of
calculation as described by Liu et al. (34) and previously by
our group (6). This technique relies on the simultaneous
measurement of aortic flow volume and associated driving
pressure, together with aortic root dimensions. Systemic
arterial compliance is then calculated from the following
formula: SAC 5 Ad/(R[Ps 2 Pd]), where Ad 5 diastolic
area; R 5 total peripheral resistance; and Ps and Pd 5
end-systolic and end-diastolic blood pressure, respectively
(6,35). Flow velocity of the ascending aorta was measured
from the suprasternal notch using a continuous wave hand-
held Doppler flow velocimeter (Multi Dopplex II, Hunt-
leigh Technology, Cardiff, United Kingdom) (6,35). Aortic
root dimensions were assessed by two-dimensional echocar-
diography (ATL, HDI Ultramark 9, Seattle, Washington),
with measurements taken from the point of insertion of the
aortic valve leaflets. Aortic root pressure was estimated by
noninvasive applanation tonometry of the right carotid
artery using a Millar Mikro-Tip pressure transducer (model
SSD-713, Millar Instruments, Houston, Texas).
Biochemical techniques. ISOLATION OF LDL AND ASSESS-
MENT OF LDL PARTICLE SIZE. Using density gradient ultra-
centrifugation, LDL cholesterol was isolated from ethyl-
enediamine tetra-acetic acid (EDTA) plasma, as previously
described (36). The LDL particle diameter was assessed by
nondenaturing polyacrylamide gradient gel electrophoresis
(Gradipore, N.S.W., Australia), as previously described
(37).
ASSESSMENT OF PLASMA AND LDL VEC. The measurement
of plasma vitamin E was performed using reverse phase high
performance liquid chromatography using an ultraviolet
absorption detector, as described previously (38). The VEC
of LDL was measured on LDL previously isolated by
ultracentrifugation, using high performance liquid chroma-
tography with a Spherisorb ODS-2, 5-mm analytic column
(Alltech Associates, Baulkham Hills, NSW, Australia) and
with standard purchased from Sigma Chemicals (St. Louis,
Missouri) and expressed as a ratio of LDL vitamin E to
LDL cholesterol in mmol/mmol LDL.
ASSESSMENT OF LDL OXIDATIVE SUSCEPTIBILITY. Low
density lipoprotein was isolated by density gradient ultra-
centrifugation as described earlier. Assessment of oxidative
susceptibility was performed using a technique originally
described by Esterbauer et al. (39) and modified by Mc-
Dowell et al. (40). Copper (5 mmol) was added to isolated
LDL diluted to 150 mmol/liter cholesterol in phosphate-
buffered saline. After the generation of products resulting
from the oxidation of lipids, absorbance was measured at
234 nm. The lag time was calculated as the time intercept
between the line of maximal slope of the propagation phase
of this reaction and the baseline absorbance at time 5 0.
Power calculation. On the basis of previous interventional
studies using FMD, we performed a power calculation
expecting to observe a 4% to 5% difference in FMD,
resulting from active treatment. Thus, with 90% power at
p , 0.01, we calculated that between 16 and 20 patients
would be required in each of the placebo and active therapy
subgroups.
Statistical analysis. The clinical characteristics are ex-
pressed as the mean value 6 SD. Data are expressed as the
mean value 6 SEM. Statistical analysis was performed
using the Statview 4.5 software program. The differences
between groups, with respect to clinical characteristics,
FMD, NTG-induced dilation and SAC at baseline, were
analyzed using the unpaired t test. Two-way repeated
measures analysis of variance (ANOVA) was used to com-
pare the effects of treatment (vitamin E or placebo) on
FMD, NTG, SAC and the vasodilator response to sodium
nitroprusside and ACh with post hoc testing using the
Scheffe´ F test. The data for which ANOVA was used are
presented in each case as follows: p value for treatment by
period interaction effect, p value for treatment effect and p
value for period effect. Linear regression analyses were
performed to examine the relations between the change in
oxidative susceptibility of LDL, LDL VEC and physiologic
variables, FMD, the response to ACh and arterial compli-
ance. Statistical significance was accepted at p , 0.05.
Table 2. Lipid Profiles and Vitamin E Concentrations Before Treatment in the Placebo and
Active Therapy Subgroups
Placebo Group
(n 5 21)
Vitamin E Group
(n 5 20)
Total cholesterol (mmol/liter) 5.4 6 0.4 5.1 6 0.2
LDL-C (mmol/liter) 3.3 6 0.3 3.1 6 0.2
HDL-C (mmol/liter) 1.4 6 0.1 1.5 6 0.1
TG (mmol/liter) 1.2 6 0.2 1.3 6 0.3
LDL particle size (nm) 25.6 6 0.1 25.6 6 0.1
Plasma vitamin E (mmol/l) 19.0 6 1.5 19.7 6 1.4
LDL vitamin E content (mmol/mmol LDL) 2.0 6 0.2 2.2 6 0.2
Lag time to LDL oxidation (min) 76.2 6 2.8 76.7 6 2.8
Data are presented as the mean value 6 SD.
HbA1C 5 glycosylated hemoglobin; HDL-C 5 high density lipoprotein cholesterol; LDL-C 5 low density lipoprotein
cholesterol; TG 5 triglycerides.
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RESULTS
Baseline biochemical, clinical and morphometric charac-
teristics. Baseline clinical, morphometric and biochemical
characteristics of the diabetic subgroups randomized to
placebo or vitamin E are shown in Tables 1 and 2. There
were no significant differences in these variables between the
two groups, with glycosylated hemoglobin levels indicating
moderate glycemic control. There was no significant differ-
ence in the mean lipid levels of the diabetic group and a
matched group of healthy control subjects from our labora-
tory, although six of these subjects had a cholesterol level
.5.5 mmol/liter but were not on lipid-lowering therapy
(equal numbers in placebo and vitamin E groups). In
addition, four diabetics smoked (equal numbers in placebo
and vitamin E groups). Plasma vitamin E was not different
at baseline between the placebo and vitamin E–treated
subgroups. After active therapy, plasma vitamin E increased
by 105%, from 19.7 6 1.4 to 40.3 6 3.9 mmol/liter. This
was accompanied by a 127% increase in LDL VEC, from
2.2 6 0.2 to 5.0 6 0.3 mmol/mmol (Fig. 1). Vitamin E
supplementation did not affect any lipid or glycemic vari-
ables.
Conduit vessel responses. ENDOTHELIUM-DEPENDENT
VASODILATION IN THE BRACHIAL ARTERY (FMD). Baseline
brachial artery diameter and FMD were not different
between the placebo and active therapy diabetic subgroups
(4.3 6 0.2 vs. 4.2 6 0.1 mm, p 5 NS and 2.4 6 0.7% vs.
2.6 6 0.6%, p 5 NS, respectively) (Fig 2a). There was no
time-dependent change in FMD in the diabetic subgroup
randomized to placebo therapy (2.4 6 0.7% before therapy
vs. 2.5 6 0.6% after therapy, p 5 NS) (Fig. 2a). However,
in the active therapy subgroup, there was a significant
improvement in FMD in response to vitamin E supplemen-
tation (2.6 6 0.6% vs. 7.0 6 0.7%; ANOVA: p , 0.0001
for treatment by period interaction effect, p , 0.0084 for
treatment effect and p , 0.0001 for period effect).
For the study cohort as a whole, baseline FMD was a
function of LDL VEC (r 5 0.38, p , 0.05), but not plasma
vitamin E. Furthermore, there was a correlation between
the change in FMD at the end of three months of treatment
and the change in LDL VEC (r 5 0.42, p , 0.05) (Fig. 3a).
There was no relation between FMD after vitamin E
therapy and LDL particle size or other variables of the lipid
profile. Ambient glucose at the time of FMD measurement
was similar both before and after treatment in both the
active therapy and placebo subgroups.
Figure 1. a, Plasma VEC in placebo subgroup (striped bars at baseline;
solid bar after treatment) and vitamin E–treated subgroup (open bar at
baseline; solid bar after treatment). b, Low density lipoprotein VEC in
placebo subgroup (striped bars at baseline; solid bar after treatment) and
vitamin E–treated subgroup (open bar at baseline; solid bar after treat-
ment).
Figure 2. a, Flow-mediated dilation in placebo subgroup (striped bars at
baseline; solid bar after treatment) and vitamin E–treated subgroup (open
bar at baseline; solid bar after treatment). Flow-mediated dilation was not
altered in the placebo group, but showed a significant increase after vitamin
E therapy. b, Nitroglycerin-induced vasodilation. After vitamin E supple-
mentation, there was a trend toward an improvement in the NTG
response.
Figure 3. a, Relation between the change (D) in FMD and the change in
LDL VEC at follow-up in the cohort. As the DLDL vitamin E increases,
so does the magnitude of DFMD (r 5 0.42, p , 0.05). b, Relation between
DFMD and the change in lag time to oxidation of LDL at follow-up.
Reduced oxidative susceptibility after vitamin E supplementation is asso-
ciated with improved FMD (r 5 0.64, p , 0.0001).
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ENDOTHELIUM-INDEPENDENT VASODILATION IN THE BRA-
CHIAL ARTERY (NTG). There was no difference in baseline
brachial artery diameter before the assessment of NTG
between the placebo and active therapy subgroups (4.3 6
0.2 vs. 4.2 6 0.2 mm, p 5 NS). There was no time-
dependent effect on the response to NTG in the placebo
subgroup (13.8 6 1.3% vs. 13.6 6 1.2%, p 5 NS) (Fig. 2b).
In the subgroup receiving active therapy, there was a trend
toward an increase in NTG after treatment (13.2 6 1.3% vs.
16.2 6 1.1%; ANOVA: p 5 0.08 for treatment by period
interaction effect, p 5 0.62 for treatment effect and p 5 0.16
for period effect (Fig. 2b). There was no relation between
NTG and LDL VEC or LDL particle size.
Resistance vessel responses. REST FOREARM BLOOD
FLOW. There was no time-dependent change in basal flow
in either the placebo subgroup (2.8 6 0.5 vs. 2.7 6
0.3 ml/min per 100 ml forearm tissue; p 5 NS by ANOVA)
and no effect of vitamin E on rest flow (2.8 6 0.5 vs. 2.7 6
0.3 ml/min per 100 ml forearm tissue; p 5 NS by
ANOVA).
ENDOTHELIUM-DEPENDENT VASODILATION. Intra-arterial
infusion of ACh produced a dose-dependent increase in
forearm blood flow in both diabetic subgroups (p , 0.005).
There was no difference in the response to the graded
infusion of ACh between the two subgroups before treat-
ment. There was no time-dependent change in the dose-
response to ACh in the placebo subgroup (Fig. 4). How-
ever, there was augmentation in the responses to ACh in the
active vitamin E–treated subgroup (ANOVA: p 5 0.04 for
treatment by period interaction effect, p , 0.01 for treat-
ment effect, and p , 0.0001 for period effect). At the
highest dose of ACh, the maximal vasodilator response
increased from 9.6 6 1.3 to 15.3 6 1.2 ml/min per 100 ml
forearm tissue (p , 0.0005) in the active therapy subgroup.
The slope of the dose-response curve increased from 0.30 6
0.04 to 0.46 6 0.04 (p , 0.0005).
ENDOTHELIUM-INDEPENDENT VASODILATION. There was
no difference in the baseline response to sodium nitroprus-
side between the diabetic subgroups randomized to active
therapy or placebo (4.2 6 0.4 vs. 4.9 6 0.8 ml/min per
100 ml forearm tissue; p 5 NS). After three months of
placebo therapy, the endothelium-independent response to
sodium nitroprusside was not different (4.2 6 1.3 vs. 3.6 6
0.6 ml/min per 100 ml forearm tissue; p 5 NS). There was
no difference in the magnitude of change in forearm blood
flow between the placebo and active treatment subgroups
after therapy (3.6 6 0.2 vs. 3.7 6 0.3 ml/min per 100 ml
forearm tissue; p 5 NS).
Systemic arterial compliance. Systolic, diastolic, pulse,
mean arterial pressure and heart rate were similar in the two
diabetic subgroups. There was no difference in SAC be-
tween the two groups before treatment (0.41 6 0.03 vs.
0.46 6 0.04 acu, p 5 NS). There was no time-dependent
change in SAC in the placebo subgroup (0.41 6 0.04 before
placebo vs. 0.47 6 0.04 acu after placebo; p 5 NS by
ANOVA). Furthermore, SAC was not altered by active
therapy with vitamin E (0.46 6 0.04 vs. 0.53 6 0.06
arbitrary compliance units; p 5 NS by ANOVA).
Oxidative susceptibility of LDL and endothelial vasodi-
lator function. The lag time to oxidation of LDL was
similar at baseline in the placebo and vitamin E subgroups
(76.2 6 2.8 vs. 76.7 6 2.8 min, p 5 NS). There was no
time-dependent change in oxidative susceptibility of LDL
in the placebo subgroup (76.2 6 2.8 vs. 74.7 6 2.9 min, p 5
NS). After three months of vitamin E therapy, the lag time
to oxidation of LDL increased by 28% (76.7 6 2.8 vs.
98.2 6 4.2 min; ANOVA: p , 0.0001 for treatment by
period interaction effect, p , 0.05 for treatment effect and
p , 0.0001 for period effect). The change in oxidative
susceptibility of LDL was related to LDL VEC (r 5 0.57,
p , 0.001). In turn, the change in FMD was related to the
change in oxidative susceptibility of LDL after either
placebo administration or treatment with vitamin E (r 5
0.64, p , 0.0001) (Fig. 3b).
DISCUSSION
We have previously shown that plasma vitamin E and LDL
VEC are reduced in young subjects with type I DM and
that LDL VEC correlates with the integrity of endothelial
function (18). We therefore hypothesized that vitamin E
supplementation might restore endothelial function in this
group. A double-blind, placebo-controlled study design was
used to assess the effect of vitamin E on 1) EVF in both the
conduit and resistance vessels; and 2) SAC in a group of
young subjects with type I DM and no evidence of macro-
vascular or microvascular disease. We observed that short-
term (three months) treatment with 1,000 IU of oral
all-rac-alpha-tocopherol improves conduit and resistance
vessel EVF, but not SAC, in type I DM. Responses to
FMD and the graded intrabrachial infusions of the
endothelium-dependent vasodilator ACh were improved in
Figure 4. Absolute forearm blood flow (a) and absolute forearm vascular
resistance (b) during graded intra-arterial infusion of ACh before (open
circles) and after (solid circles) therapy with vitamin E and before (open
squares) and after (solid squares) placebo. Absolute forearm blood flow
and vascular resistance were augmented after vitamin E therapy, but there
was no change in the response in the placebo group (ANOVA, p , 0.05).
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the diabetic subgroup randomized to active therapy. Fur-
thermore, the change in FMD after treatment was directly
related to the change in LDL VEC and the change in the
oxidative susceptibility of LDL.
There were no differences in the baseline characteristics
between the diabetic groups randomized to placebo or active
therapy, indicating successful randomization into two com-
parable groups. Importantly, we observed no time-
dependent effects on vascular reactivity or biochemical
measurements in the placebo group, thus providing a stable
set of subjects with which to compare the effects of vitamin
E supplementation.
The aim of supplementation with vitamin E was to
increase LDL VEC levels and thereby reduce the oxidative
susceptibility of LDL. One thousand IU of vitamin E was
specifically chosen to at least double LDL VEC. This was
achieved with a 127% increase and a corresponding 28%
increase in the lag time to oxidation of LDL. The change in
lag time of LDL was directly related to the change in LDL
VEC.
Previous studies. Vitamin E has been shown to improve
endothelium-dependent relaxation in experimental models
of diabetes (19,20). To the best of our knowledge, this is the
first study in diabetic subjects to demonstrate improved
endothelial function with this antioxidant, although a recent
study showed no benefit from eight weeks of vitamin E
therapy (1,600 IU) in subjects with type II DM. Intra-
arterial infusion of the water-soluble antioxidant vitamin C,
however, has been shown to improve resistance vessel
endothelial function in subjects with both type I (41) and
type II DM (42), suggesting that oxygen-derived free
radicals contribute to abnormal vascular reactivity in diabe-
tes, probably by quenching nitric oxide. Our study is the first
to investigate the effect of vitamin E therapy on endothelial
function and arterial compliance in subjects with type I
DM, and it highlights the fact that impaired EVF can be
improved in a relatively short period with appropriate
interventions.
Mechanisms of action of vitamin E. The improvement in
EVF observed in this study appears to be related to an
improvement in the oxidative susceptibility of LDL, in view
of the direct relation between these two variables. Consis-
tent with this, a relation between improvement in EVF and
a reduction in measures of oxidation of LDL has been
observed in other studies after vitamin E supplementation
(43–45). There is evidence that a reduction in oxidized
LDL would be expected to increase nitric oxide bioavail-
ability (46–48) and thus improve endothelium-dependent
vasodilation.
Activation of PKC occurs in diabetes (14) as a result of
hyperglycemia (49) and oxidized LDL (50). This activation
of PKC also reduces nitric oxide bioavailability through a
number of mechanisms, including downregulation of nitric
oxide synthase activity (51). The fact that vitamin E is an
efficient inhibitor of PKC (50) provides a further mecha-
nism by which this compound may improve EVF, which is
distinct from its antioxidant action.
Long-term administration of vitamin E has been shown
to improve insulin sensitivity (52), which itself may improve
endothelial function. In this study, we did not measure
insulin action, but there was no effect of vitamin E on
glycemic control subjects, as measured by glycosylated
hemoglobin levels. Moreover, the effect of vitamin E cannot
be simply explained on the basis of a change in the lipid
profile per se, as has been seen in animal models. Total,
LDL and high density lipoprotein cholesterol and LDL
particle size were not affected by vitamin E, and are
therefore unlikely to account for the improvement in endo-
thelial function we observed. Vitamin E also inhibits leu-
kocyte adhesion to endothelial cells (53) by inhibiting the
expression of adhesion molecules (54), as well as monocyte
transmigration (55). These multiple effects on the vascular
system probably underlie the epidemiologic (15,16) and
clinical studies (17,56) demonstrating a benefit with regard
to vascular disease from vitamin E.
Nitroglycerin response. We observed a trend toward an
improvement in the brachial artery response to sublingual
NTG in the diabetic subgroup randomized to active ther-
apy. Consistent with this, a recent study in hypercholester-
olemic subjects demonstrated an improvement in
endothelium-independent vasodilation after vitamin E
therapy (57). The response to NTG is partly flow-mediated,
consequent on some increase in forearm blood flow. Thus,
restoration of FMD might also improve the vasodilator
response to NTG. Nitroglycerin is, of course, biotrans-
formed to nitric oxide. The brachial artery responses to
NTG may also have improved as a result of the effects of
vitamin E on the cyclic guanosine monophosphate signal
cascade in smooth muscle cells or simply through reduced
deactivation of exogenous nitric oxide.
Improvement in the NTG response may have been more
apparent if we had studied a larger number of diabetic
subjects. We therefore cannot be certain that vitamin E did
not cause a more generalized improvement in vascular
reactivity which accompanied an improvement in
endothelium-dependent relaxation, although there was no
improvement in the response to sodium nitroprusside in the
resistance circulation.
Systemic arterial compliance. We and other investigators
have previously documented a reduction in SAC in subjects
with type I DM (5,6). This is most likely due to a
combination of genetic, metabolic and hormonal alterations
(58) leading to structural alterations of the arterial wall.
However, there is some evidence that the endothelium,
through the generation of vasoactive mediators such as
nitric oxide or endothelin, may influence arterial stiffness
(59). Moreover, data in older subjects without vascular
disease suggest that vitamin E can improve impaired arterial
compliance (28). This effect might be the result of improved
EVF, a reduction in activated PKC (60) or perhaps an effect
on vascular smooth muscle cell proliferation (61). In this
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study, however, we did not observe any change in SAC in
patients randomized to active therapy. This suggests that
endothelium-dependent vascular reactivity may be altered
more readily by vitamin E, as compared with abnormalities
of the arterial wall structure in early diabetic vascular
disease.
Discrepancies in response to vitamin E. The effect of
vitamin E therapy on EVF has been studied in hypercho-
lesterolemic patients, with some (57,62) but not all (24–26)
studies showing a beneficial effect. The lack of consistency
in the results with hypercholesterolemic patients may pos-
sibly be explained by concomitant lipid-lowering therapy
(26), combination therapy with antioxidants (24), lower
doses of vitamin E (25), a shorter duration of treatment
(24–26), smaller numbers of patients (63) or more advanced
disease (25). Differences in the pathophysiology of vascular
dysfunction in type I DM and hypercholesterolemia may be
another alternative to explain the inconsistency in the results
of antioxidant studies. In this regard, activation of PKC in
diabetes might be expected to promote the development of
vascular disease to a greater extent than in hypercholester-
olemia. Reversal of PKC activation by vitamin E (14) could
therefore have a greater effect on vascular reactivity in
diabetic subjects. It is not clear, however, why no benefit
from vitamin E therapy was seen in subjects with type II
DM recently, although a shorter duration of therapy, older
subjects, a different dose of vitamin E or higher baseline
levels of vitamin E may be relevant (27).
Potential limitations. It is possible that we would have
seen an increase in the vasodilator response to sodium
nitroprusside after vitamin E therapy if we had used more
than one dose. For this reason, a nonspecific improvement
in vascular function in the resistance circulation cannot be
excluded, as is the case in the brachial artery.
Concern has been raised over potential pro-oxidant ef-
fects of vitamin E (64), which could be an explanation for
some of the negative findings in subjects with hypercholes-
terolemia. However, a key study in a rabbit model, which
further raised these concerns, demonstrated adverse effects
on endothelial function at much higher comparative doses
than those used in our study (22). It is also notable that one
of the studies in hypercholesterolemic subjects which did
show a benefit with vitamin E also used a dose of
1,000 IU/day (62). This suggests that vitamin E at this dose
is unlikely to have physiologically important pro-oxidant
effects in humans.
Vitamin E is a generic term that includes all entities that
exhibit the biologic activity of alpha-tocopherol. In nature,
eight substances (comprising the tocopherols and tocotrien-
ols) exhibit biologic activity. d-Alpha-tocopherol is the
predominant form and has the highest biopotency. Syn-
thetic vitamin E may be a mixture of stereoisomers of
alpha-tocopherol, but is usually either d-alpha-tocopherol
or all-rac-alpha-tocopherol. In this study, we used all-rac-
alpha-tocopherol. There has been controversy in the pub-
lished data regarding the relative biologic potencies of these
stereoisomers. This may have considerable relevance with
respect to the conflicting results of epidemiologic and
interventional studies that relate to natural or synthetic
vitamin E. Thus, possible differences in the biopotency of
vitamin E need to be borne in mind when interpreting study
results. It is possible in this study that a different stereoiso-
mer may have improved endothelium-independent vasodi-
lation to a greater extent or may have improved arterial
compliance. This requires further study.
Conclusions. We have shown, for the first time to our
knowledge, in a randomized, double-blind, placebo-
controlled study, that vitamin E therapy can improve both
conduit and resistance vessel EVF in young subjects with
type I DM in a relatively short period. Moreover, this
improvement in EVF was directly related to increased LDL
VEC and reduced oxidative susceptibility of LDL. Systemic
arterial compliance, however, was not affected. These find-
ings suggest that vitamin E may have a role in the
management of early vascular disease in subjects with type I
DM.
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